Connect
MJA
MJA

Conflicting information from TGA versus FDA may undermine compliance with use of medication

Klaus Martin Beckmann
Med J Aust 2013; 199 (1): 28-29. || doi: 10.5694/mja13.10086
Published online: 8 July 2013

To the Editor: Conflicting information about treatments is known to undermine compliance with the use of medications.1 The education of patients and caregivers that accompanies prescribing should therefore be as consistent as possible. Clients may conduct research on the internet into particular medicines and try to corroborate “what the doctor said”. In the case of the use of clonidine in children, publicly available information is conflicting. The websites of two regulatory agencies, the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States, give conflicting information on using this α-2 adrenergic agonist. Doctors in Australia may refer patients to the TGA website for information on clonidine, but in doing so will only provide information on the use of clonidine for hypertension. However, paediatricians and child and adolescent psychiatrists may use clonidine (following guidance used in other countries) in children and adolescents for diverse beneficial effects in managing attention deficit-hyperactivity disorder (ADHD), outside its TGA-approved use.2

The TGA’s consumer medical information (CMI)3 and product information (PI)4 for clonidine state:

The Pharmaceutical Benefits Scheme website has hyperlinks to both PI and CMI on the website of the TGA.

A problem arises if a client seeks information about prescribed medication from other jurisdictions such as the US. In their statistical review and evaluation of clonidine, the FDA states, based on most recent evidence, that:

Therefore compliance with medication regimens may be undermined by conflicting information from the TGA and FDA. Clinicians need to be aware of the differences in information and recommendations disseminated by authoritative sources and be prepared when they counsel patients. Perhaps the TGA should review its CMI and PI to reflect recent evidence that clonidine, with the necessary cautions, can be safely prescribed to some selected children and adolescents.

  • Klaus Martin Beckmann1

  • Evolve Therapeutic Services, Queensland Health, Brisbane, QLD.



Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.